1. In Vivo

Locked And Bolted: How To Create A Data Fortress

 
• By Jo Shorthouse

Considering the increasing number of biopharmaceutical companies pursuing more virtual and digital tools, the need for world class digital protection is a pressing challenge. In Vivo talks to two cyber security experts about best practice when securing data assets.

Padlock With Keyhole icon in personal data security Illustrates cyber data or information privacy idea.
• Source: Shutterstock

The way in which companies interact with their employees, customers and regulators is increasingly virtual. The COVID-19 pandemic has catalyzed satellite working practices with staff setting up offices at home, often for the first time.

While the global biopharmaceutical industry has also adhered to this new way of working, it has been embracing digital tools and creating an online working toolkit for the last decade

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.